Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04557826 · ClinicalTrials.gov registry record · NA

Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens

A NA study, sponsored by EmitBio.

Completed
Registry status
NA
Development phase
25
Enrollment target

NCT04557826: Completed NA study, sponsored by EmitBio.

NCT04557826 is a NA study that has completed, run by EmitBio. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04557826, a NA study, has completed, sponsored by EmitBio.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target

Study Summary

This first-in-man (FIM) phase I study will evaluate the acute safety, tolerability, and acceptability of the investigational RD19 device among 25 healthy volunteers between the age of 18 and 45.

Primary Outcome

* Ease of device use (Likert Scale 1 -10) * Clarity of user instructions (Likert Scale 1-10) * Compliance with per protocol schedule (# times missed / 28) and, if out of compliance, reason(s) for noncompliance (collected as verbal string).

Interventions

  • DEVICE RD19

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2020-08-31
Est. Completion 2020-12-07
Phase NA
EmitBio

5 total trials

What the finished NCT04557826 record still lists

NCT04557826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which RD19 is the first listed.

NCT04557826 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04557826 about?

NCT04557826 is a clinical study titled "Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens". This first-in-man (FIM) phase I study will evaluate the acute safety, tolerability, and acceptability of the investigational RD19 device among 25 healthy volunteers between the age of 18 and 45.

What is the current status of trial NCT04557826?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-08-31. Estimated completion is 2020-12-07.

What interventions are being tested in trial NCT04557826?

The interventions under investigation include: RD19 (DEVICE).

Who is sponsoring clinical trial NCT04557826?

This trial is sponsored by EmitBio, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04557826's enrollment target sits among peer trials

25 1712th of 2000 higher than 265 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04557826, the US trial registry maintained by the National Library of Medicine. NCT04557826 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.